This is a notice of intent for a sole source award to Illumina, Inc. for a maintenance agreement for the Illumina NovaSeq X Plus sequencer at the National Institutes of Health (NIH) Clinical Center. The acquisition is being conducted using FAR Part 13 simplified acquisition procedures. Interested parties may identify their interest and capabilities by submitting comments to the NIH, Clinical Center, Office of Purchasing and Contracts, to the attention of Kristin Nagashima via email by May 5, 2026, at 11 am EST.
The bid notice does not specify a delivery deadline for the maintenance agreement.
The bid notice does not specify payment terms.
The bid notice does not specify warranty information.
The bid notice states that the award will be on a firm fixed price sole source award basis.
The bid notice does not explicitly state qualification criteria, but it implies that Illumina, Inc. is the only qualified source due to manufacturing and servicing the instrument.
The bid notice does not specify penalties.
The bid notice does not mention a site visit.
The bid notice does not require sample submission.
Comments to this announcement may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Kristin Nagashima, Contract Specialist via email to ***@***. *. * by May 5, 2026 at 11am EST.
The bid notice does not specify the estimated total value.